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Localization and function of ET-1 and ET receptors in small
arteries post-myocardial infarction: Upregulation of smooth muscle
ETB receptors that modulate contraction
*,1,2Gillian A. Gray, 1,4Emma J. Mickley, 1,3David J. Webb & 1,5Pauline E. McEwan
1Endothelial Cell Biology and Molecular Cardiology Section, Centre for Cardiovascular Science, University of Edinburgh, Hugh
Robson Building, George Square, Edinburgh EX8 9XD; 2Department of Biomedical Sciences, University of Edinburgh, Hugh
Robson Building, George Square, Edinburgh EH8 9XD and 3Department of Medical Sciences, Western General Hospital,
Edinburgh EH4 2XU
1 Endothelin-1 (ET-1) has been implicated as a mediator of increased vascular tone during
development of heart failure post-myocardial infarction (MI). In the present study, expression and
pharmacology of ET-1 and its receptors were studied in small mesenteric arteries from rats at 5 and
12 weeks after coronary artery ligation for induction of MI, or sham-operation.
2 In vessels from sham-operated and 5 week post-MI rats preproET-1mRNA, immunoreactive (ir)
ET-1, ETB receptor mRNA and irETB receptor were confined to the endothelium, while ETA
receptor mRNA was distributed throughout the media. At 12 weeks post-MI, preproET-1 and
irETA receptor localization was similar but ETB receptor mRNA and immunoreactivity were
detectable in the media, as well as the endothelium.
3 The ET-1 concentration-response curve (CRC) was progressively shifted to the right in
pressurized third generation mesenteric arteries from 5 and 12 week post-MI rats relative to sham-
operated rats, with no change in the maximum. The ETA receptor antagonist BQ-123 (10
76
M)
induced a rightward shift of the ET-1 CRC in all vessels. Desensitization of ETB receptors, by
exposure to SRTX S6c (361078 M), had no eect on the ET-1 CRC in vessels from 5 week post-MI
or sham-op rats but induced a leftward shift in vessels from 12 week post-MI rats.
4 These results identify the endothelium as the primary site of ET-1 synthesis in small arteries and
the ETA receptor as mediating the eects of ET-1 in these vessels. However, ETB receptor expression
increases in vascular smooth muscle post-MI and is linked to mechanisms that inhibit the contractile
response to ET-1.
British Journal of Pharmacology (2000) 130, 1735 – 1744
Keywords: Coronary artery ligation; endothelin; endothelin receptors; ETA; ETB; vascular smooth muscle; myocardial
infarction; heart failure; small mesenteric arteries
Abbreviations: ACh, acetylcholine; BCIP, 5-bromo-4-chloro-3-indolyl phosphate; BQ-123, (cyclo[D-Trp-D-Asp-L-Pro-D-Val-L-
Leu]); CAL, coronary artery ligation; CHF, chronic heart failure; CRC, concentration-response curve; DAB,
diaminobenzidine; DIG, digoxigenin; ETA, endothelin type A receptor; ETB, endothelin type B receptor; ET-1,
endothelin-1; ir, immunoreactivity; KCl, potassium chloride; KH, Krebs-Henseleit solution; MI, myocardial
infarction; NBT, nitro-blue tetrazolium chloride; PE, phenylephrine; SRTX S6c, sarafotoxin S6c
Introduction
Systemic vasoconstriction and reduced peripheral perfusion
contribute to the vicious cycle that leads to the development
of chronic heart failure (CHF) post myocardial infarction
(MI). While augmented adrenergic activity and stimulation
of the renin-angiotensin system have been implicated as
mediators of increased vascular tone in this process,
blockade of both systems is ineective in normalizing
peripheral resistance, or in preventing the high mortality
associated with CHF (Dargie & McMurray, 1994). Plasma
concentrations of the potent vasoconstrictor peptide en-
dothelin-1 (ET-1) and its precursor big ET-1 are increased
post MI and levels increase in proportion to the
symptomatic and haemodynamic severity of CHF (Rode-
heer et al., 1992; Pacher et al., 1993; Wei et al., 1994). ET-
1 has thus emerged as a potential mediator of the increased
peripheral vascular resistance that contributes to progression
of CHF post-MI.
The actions of ET-1 are mediated via ET-1 selective ETA
receptors and ET isopeptide unselective ETB receptors (Gray
& Webb, 1996). Antagonists of both receptor subtypes are
now available and a number are in development for use in
diseases where there is evidence of a pathophysiological role
for ET-1 (Gray et al., 2000). In order to apply the most
eective therapy it is important to characterize the receptors
mediating the actions of ET-1 and to understand what the
consequences of blockade of these receptors might be. In
healthy blood vessels both ETA and ETB receptors are found
on smooth muscle cells where they mediate the constrictor
eects of ET-1, produced by vascular endothelial cells.
Activation of ETB receptors on endothelial cells results in
the liberation of endothelium-derived relaxing factors that
cause vasodilatation (D’Orleans-Juste et al., 1993). In most
vessels studied the ETA receptor is the principal subtype
mediating smooth muscle contraction (Davenport et al.,
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1995), although the ETB subtype can make a significant
contribution (Haynes et al., 1995), particularly on the low
pressure side of the circulation (Moreland et al., 1992; Gray
et al., 1994; Strachan et al., 1995). In addition, smooth
muscle ETB receptors can influence ETA receptor mediated
contraction through intracellular cross-talk mechanisms
(Fukuroda et al., 1994b; Clozel & Gray, 1995; Mickley et
al., 1997a; Ozaki et al., 1997). A physiological role for ET-1
in the regulation of vascular tone in man has been
demonstrated by infusion of ETA receptor antagonists,
either locally into the forearm where they increase blood
flow, or systemically, where they reduce mean arterial blood
pressure and peripheral vascular resistance (Haynes et al.,
1995; 1996). Systemic infusion of a selective ETB receptor
antagonist results in peripheral vasoconstriction in experi-
mental animals (Allcock et al., 1995) and in man (Strachan
et al., 1999), demonstrating that liberation of relaxing
factors is the principle role of ETB receptor activation in
healthy vasculature.
In cardiovascular pathophysiology there is increasing
evidence for an alteration in the balance of receptors
mediating the actions of ET-1 in blood vessels. While this
can be explained in part through endothelial dysfunction
which reduces the influence of endothelial ETB receptor
activation (Hasdai et al., 1997; Haynes & Webb, 1998;
Kakoki et al., 1999), there is also evidence for changes in the
expression and function of smooth muscle ET receptors.
Downregulation of both ETA and ETB receptors occurs in
hypertension (Schirin et al., 1995; Touyz et al., 1995) and
ETB receptor expression or function is reported to be
increased in atherosclerosis (Dagassan et al., 1996), in
spontanously hypertensive rats (Batra et al., 1993), in
diabetes (Sullivan et al., 1997) and in response to increased
flow (Barber et al., 1996). In CHF, there is functional
evidence to support vascular ETB receptor upregulation in
patients (Love et al., 1996) and in an animal model (Cannan
et al., 1996). ETA receptor expression is reported to be
decreased post-MI in mesenteric arteries (Fu et al., 1993).
These eects might be associated with a phenotypic change of
vascular smooth muscle cells in disease (Adner et al., 1998;
Eguchi et al., 1994; Owe-Young et al., 1999), or they might
occur under the influence of angiotensin II (Kanno et al.,
1993) or ET-1 itself (Hamilton et al., 1994; Hirata et al.,
1988). Circulating levels of ET-1 and its big ET-1 precursor
are increased in a range of cardiovascular diseases, due to
increased synthesis or reduced clearance (Haynes & Webb,
1998). In the vasculature, smooth muscle cells that are
normally the target cell for ET-1 can generate ET-1 in
pathology e.g. in coronary artery disease, in hypertension, or
in tissue culture (Yu & Davenport, 1995; Schirin et al.,
1997; Dashwood et al., 1998; Rossi et al., 1999).
The sites of ET-1 synthesis and the receptors mediating its
eects in peripheral blood vessels during progression of CHF
post-MI are not fully understood. The principal aims of the
present study were therefore to characterize the receptors
mediating the actions of ET-1 in resistance vessels from rats
which had undergone coronary artery ligation and to correlate
receptor function with distribution using in situ hybridization
and immunocytochemistry. Furthermore, as receptor expres-
sion can be influenced by local ET-1 concentration prepro ET-
1 mRNA and immunoreactive ET-1 were localized in the
blood vessel wall and plasma levels of ET-1 and big ET-1 were
measured by radioimmunoassay. Some of these data have been
presented to the British Pharmacological Society (Mickley et
al., 1997b) and to the International Society for Heart Research
(Mickley et al., 1998).
Methods
Coronary artery ligation surgery
Adult, male Wistar rats, 250 – 300 g (Charles River), were
subjected to ligation of the proximal portion of the left, main
coronary artery according to the method of Pfeer et al.
(1979). Briefly, rats were anaesthetized by injection of sodium
pentobarbital (Sagatal, 60 mg kg71 i.p.), intubated with a
plastic cannula and mechanically ventilated with oxygen
enriched room air by use of a small rodent ventilator (Harvard
Apparatus, U.K.) at a rate of 60 cycles min71 and a tidal
volume of 1 ml 100 g71 body weight. A left thoracotomy was
performed between the third and fourth ribs and the
pericardium opened. The heart was gently but rapidly
exteriorized and a 5/0 silk suture (Ethicon Ltd, U.K.) was
passed around the left, main coronary artery. Sham-operated
rats were subjected to the same protocol, except the suture was
pulled through under the artery. The heart was subsequently
returned to its position in the thorax and the rib cage closed
with a 3/0 suture. A plastic catheter connected to a 1 ml
syringe was placed in the chest before sewing and was used to
remove air from the chest after closure. The animals were
allowed to recover from anaesthesia, and were given
buprenorphine (0.3 mg kg71) subcutaneously for analgesia.
Ethical approval was granted by the Home Oce.
Plasma endothelin levels
At 5 or 12 weeks post ligation or sham operation, rats were
anaesthetized (Sagatal, 60 mg kg71 i.p.) and blood was
removed from the dorsal aorta into ice-cold tubes containing
5% EDTA for the measurement of plasma ET-1 and big ET-1
by radioimmunoassay, as previously described (Newby et al.,
1998).
Tissue preparation and measurement of infarct size
Following exsanguination, the mesenteric bed was rinsed and
sections removed into either cold Krebs-Henseleit (KH)
solution for functional studies or 10% neutral buered
formalin for fixation. After fixation the tissues were processed
in ethanol and embedded in paran wax for immunohis-
tochemistry and in situ hybridization. The hearts and lungs
were removed, rinsed in saline to remove any residual blood
and weighed. Hearts were bisected then fixed and processed as
above. Infarct size was measured in paran sections as
described previously (Mulder et al., 1998). Sections were
placed under a CCD video camera module (Sony, U.K.)
attached to a microscope with a620 lens. The endocardial and
epicardial circumferences of the infarcted tissue and of the LV
were determined with image analysis software (Imaging
Associates, Thame, U.K.). Infarct size was calculated as a
percentage of [endocardial+epicardial circumference of the
infarcted LV (mm)] / [endocardial+epicardial circumference
of the whole LV (mm)].
In situ hybridization
The method for detecting preproET-1 and ET receptor mRNA
expression in situ has been described previously (McEwan et
al., 1998). In brief, cDNA fragments subcloned into pCR 2
vector (Stratagene) were linearised with HindIII, KpnI and
EcoRI restriction enzymes. cDNA templates for preproET-1,
ETA receptor and ETB receptor were purified by phenol-
chloroform extraction. Complementary mRNA anti-sense
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probes were transcribed in the presence of digoxigenin (DIG)-
labelled uracil (Boehringer Mannheim GmBH, Germany) and
T7 and SP6 RNA polymerases. Sense probes were transcribed
using T3 polymerase. Consecutive 3 mm paran sections were
incubated with either sense or antisense DIG-labelled probes
for preproET-1, ETA receptor or ETB receptor mRNA
overnight. Following treatment with and a subsequent series
of stringent washes in standard sodium citrate/formamide,
sections were then treated with an alkaline phosphatase
conjugated anti-DIG antibody and nitro-blue tetrazolium
chloride/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP)
substrate. Prepro ET-1, ETA receptor and ETB receptor
mRNA were detected as dark blue dots within the cytoplasm
of cells in tissue sections. Transverse sections of aorta were
used as positive controls. Negative controls were treated with
RNAase prior to incubation with antisense or sense probes.
Non-specific binding of the anti-DIG antibody was blocked
using undiluted sheep serum for 1 h at 248C.
Immunocytochemistry
Immunoreactive ET-1 and ETB receptor were detected within
parallel vessel sections using anti-ET-1 (Biodesign) and anti
ETB monoclonal antibodies (Calbiochem), followed by an
alkaline phosphatase-conjugated goat anti-mouse IgG. ET-1
and ETB receptor were detected using biotinylated secondary
antibody (Dako) and a streptavidin-biotin-peroxidase kit
(Dako) followed by incubation with diaminobenzidene (DAB).
Positive signals appeared brown. Negative controls were
treated with an antibody of the same immunoglobulin class
not directed against the ET-1 epitope, or with DAB alone.
Perfusion myograph studies
Third order branches of the mesenteric artery (lumen diameters
shown in Table 2) were excised and mounted between two fine
glass cannulae (*100 – 150 mm tip diameter) in a perfusion
myograph (Living Systems Instrumentation, Burlington, VT,
U.S.A) as previously described (Mickley et al., 1997a). Briefly,
an intraluminal pressure of 60 mmHg was maintained by a
peristaltic pump connected to a pressure servo unit. The
arteries were superfused with warmed (378C) and gassed (95%
O2 and 5% CO2) KH solution (mM: NaCl 118, KCl 4.7, CaCl2
2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0 and glucose 5.5;
BDH-Merck, Dorset, U.K.) containing indomethacin (1074 M)
at a flow rate of 5 ml min71. Lumen diameter and wall
thickness were measured by video dimension analyser (Living
Systems Instrumentation, Burlington, VT, U.S.A.) calibrated
against a stage micrometer (resolution=1 mm). After an
equilibration period of 60 min the vessels were exposed twice
to modified KH solution containing 60 mM KCl (equimolar
replacement of NaCl by KCl) to produce maximum constric-
tion. In all experiments included in this study the endothelium
was removed by passage of an air bubble through the lumen of
the mounted vessel (Falloon et al., 1993). Removal of the
endothelium was confirmed by loss of acetylcholine (ACh
1076 M) induced relaxation in vessels preconstricted with the
adrenoceptor agonist phenylephrine (PE, 1075 M).
Cumulative agonist concentration-response curves (CRC)
were obtained by addition of ET-1 (10713 – 361078 M) or
SRTX S6c (10712 – 361078 M) to a 30 ml KH reperfusion
circuit as previously described (Mickley et al., 1997a).
Responses were recorded 5 min after addition of each agonist
concentration, which was sucient time for an equilibrium
response. All of the following studies were carried out in
random order and only one concentration response curve to
ET-1 was performed per tissue. None of the drug treatments
resulted in complete occlusion of the vessel lumen within the
concentration range studied. To study the role of the ETA
receptor, BQ-123 (1076 M) was added to the reperfusion circuit
30 min before commencement of the ET-1 CRC. To study the
role of the ETB receptor vessels were exposed to a
supramaximal concentration of SRTX S6c (361078 M) for
30 min, twice (with a wash out period of 10 min between each
exposure), prior to commencement of the ET-1 CRC to
desensitize ETB receptors (Mickley et al., 1997a). Some vessels
underwent both desensitization and exposure to BQ-123.
Peptides and reagents
ET-1 and SRTX S6c (Novabiochem, Nottingham, U.K.) were
reconstituted in 50 : 50 methanol:distilled water. BQ-123
(cyclo [D - Trp - D -Asp - L - Pro - D -Val - l - L-Leu], Neosystems,
France) was reconstituted in 0.9% saline, aliquoted and stored
frozen at 7208C until use. All peptide agonists and
antagonists were diluted in KH solution containing 0.1%
bovine serum albumin (BSA: Sigma, Poole, U.K.). In all
antagonist experiments the ET-1 concentrations were diluted
in 0.1% BSA KH solution containing the appropriate
antagonist. ACh (chloride salt, Sigma, Poole, U.K.) and PE
(hydrochloride salt; Fisons, U.K.) were prepared in saline at
stock concentration of 1072 M, aliquoted, and stored at
7208C until use when diluted in KH solution.
Data analysis
Plasma peptide concentrations, tissue weights and infarct sizes
data were analysed by one-way ANOVA and significance was
established using Bonferroni’s test. Unpaired observations
were assessed by Student’s t-test. For functional studies
responses to receptor agonists were calculated as a percentage
of maximum constriction obtained with the second exposure to
60 mM KCl Krebs solution and are expressed as mean+
s.e.mean. Where a maximum response to the agonist was
obtained, the negative log of the concentration causing half-
maximal contraction (pD2) was calculated by linear regression
Table 1 Infarct size and the eects of myocardial infarction (MI) on lung and heart weights and on plasma concentrations of ET-1
and big ET-1
Heart weight Lung weight Infarct size ET-1 Big ET-1
(g kg71 BW) (g kg71 BW) (% LV free wall) (pg ml71) (pg ml71)
5 weeks sham
5 weeks post MI
12 weeks sham
12 weeks post MI
0.64+0.05
*0.82+0.06
0.79+0.07
*1.00+0.02
0.81+0.08
1.14+0.14
0.95+0.11
1.39+0.04
No infarct
44+8
No infarct
49+11
2.8+1.0
5.4+2.0
5.0+1.6
5.6+2.6
23.4+9.2
26.6+9.4
24.7+8.8
41.6+14.7
Parameters were measured using rats at 5 or 12 weeks post myocardial infarction (MI) or sham-operation (sham), n=8 per group.
Infarct size is expressed as a percentage of the left ventricular (LV) free wall. Heart and lung weights are expressed as a proportion of
body weight (BW). Values are the mean+s.e.mean, *P<0.05 compared to age-matched sham-op.
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analysis and compared using unpaired t-test. The concentra-
tion-response curves were compared by one-way ANOVA
followed by Fisher’s least significant dierence test. A P value
of 50.05 was considered significant.
Results
Survival, infarct size and plasma ET-1/big ET-1
The survival rate for rats that underwent coronary artery
ligation for induction of myocardial infarction (MI) was
approximately 75%, all deaths occurred within 24 h of
surgery. Infarct sizes at 5 and 12 weeks post MI were
44+8% (n=8) and 49+11% (n=8) of the left ventricular
free wall, n=8. Despite significant thinning and scar formation
in the infarcted region (not shown), heart weight was
significantly increased post-MI at both time points (Table 1).
Plasma ET-1 and big ET-1 concentrations were not
significantly greater post-MI than sham controls at either of
the time points studied (Table 1).
PreproET-1 and ET-1 distribution
In situ hybridization in sections of third generation mesenteric
arteries demonstrated that pre proET-1 mRNA is confined to
the endothelial layer of the vessel wall (Figure 1a). The
presence of signal in the adventitial layer of some vessels can
Figure 1 Representative mesenteric vessel sections from sham-operated rats showing localization of (a) pre pro ET-1 mRNA, and
(b) immunoreactive ET-1 in the vascular endothelium, and (c) ETA receptor mRNA (dark dots) in the smooth muscle media.
Distribution was similar in vessels from sham-op and coronary artery ligation rats. Original magnification:6240. Figure is
representative of at least seven sections.
Figure 2 Representative mesenteric vessel sections showing localization of ETB receptor mRNA (dark dots in a,c) and ETB
receptor protein (brown staining in b,d) in the endothelium of vessels from rats 12 weeks after sham-operation (a,b). Both are seen
in medial smooth muscle in addition to the endothelium in vessels from rats 12 weeks after coronary artery ligation (c,d). Original
magnification:6240. Figure is representative of at least six sections.
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best be explained by synthesis in the endothelium of the vasa
vasorum. Production of mature ET-1 in the endothelium of
mesenteric arteries and in the vasa vasorum was confirmed by
immunocytochemistry (Figure 1b). Immunoreactive ET-1 was
seen in the medial smooth muscle layer of some vessels, most
likely resulting from binding of ET-1 to receptors on smooth
muscle cells.
ETA and ETB receptor mRNA distribution
A high level of ETA receptor expression in the medial
smooth muscle of all vessels was demonstrated by in situ
hybridization (Figure 1c). No obvious dierences in
expression of the ETA receptor were detected between the
dierent groups studied (results not shown). In contrast to
the ETA receptor, neither ETB receptor mRNA expression
nor significant immunoreactivity was detectable in the
medial layer of arteries from sham-operated rats or from
rats at 5 week post-MI (results not shown). ETB receptor
expression and immunoreactivity was confined to the
endothelial and adventitial layers of these vessels (Figure
2a,b). However, in mesenteric arteries from rats 12 weeks
post-MI there was clear evidence of ETB receptor mRNA
expression in the medial layer (Figure 2c). The presence of
Table 2 Lumen diameters of third generation mesenteric arteries at rest and in response to constrictor agents
Resting
diameter (mm)
Post KCl (60 mM)
diameter (mm)
Post PE (1075 M)
diameter (mm)
5 weeks sham
5 weeks post MI
12 weeks sham
12 weeks post MI
292+10
294+8
285+9
305+12
58+3
56+2
56+2
60+3
54+2
53+3
56+3
62+3
Third generation arteries were dissected from the mesenteric beds of rats at 5 or 12 weeks post myocardial infarction (MI) or sham-
operation (sham), n=8 per group. Vessel diameters are shown at rest and after exposure to potassium chloride (KCl, 50 mM) or
phenylephrine (PE, 1076 M) values are mean+s.e.mean, n=8.
Figure 3 Cumulative concentration-response curves to ET-1 (a, b) and SRTX S6c (c, d) in small mesenteric arteries from rats 5
weeks (a, c) or 12 weeks (b, d) after coronary artery ligation (post-MI) or sham-operation (sham-op). Agonist responses are
expressed as a percentage of the maximal contraction to KCl (60 mM) and are means+s.e.mean (n=6– 8).
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ETB receptor protein on smooth muscle cells was confirmed
by immunoreactivity (Figure 2d).
Perfusion myography
The mean lumen diameter of the small mesenteric arteries was
similar in all of the groups studied (Table 2). There was no
dierence in the maximal constriction obtained in response to
KCl or PE in the arteries from either the 5 or 12 week post-MI
rats compared to their respective sham-operated controls
(Table 2).
ET-1 constricted all arteries in a concentration-dependent
manner (Figure 3). There was no significant dierence in the
response to ET-1 of arteries taken from rats at 5 weeks post-
MI relative to age matched sham-operated rats (pD2 values
9.3+0.2 and 9.2+0.2 respectively, n=8 per group, Figure 3a)
However, by 12 weeks post surgery the ET-1 CRC was
significantly shifted to the right in arteries from post-MI rats
relative to sham-operated controls (ANOVA P50.04; pD2
values 9.5+0.2 and 8.9+0.2 respectively, P50.05, n=8 per
group, Figure 3b), although there was no change in the
maximum response.
In contrast to ET-1, contractile responses to the ETB
receptor agonist SRTX S6c were small and variable in vessels
from sham-operated and post-MI rats at both time points
studied (Figure 3c,d). At 12 weeks post-MI only one of the six
arteries exposed to SRTX S6c responded to it by contracting.
ETA receptor antagonism with BQ-123 caused a rightward
shift of the ET-1 CRC in arteries from both 5- and 12-week
sham-operated animals (Figure 4a,b). However, in arteries
from rats post MI the eect of BQ-123 on the ET-1 CRC could
be dierentiated from that in the respective age-matched sham-
operated controls. At 5 weeks post-MI BQ-123 inhibited
responses to ET-1 above 1079 M but had no significant eect
Figure 4 The eect of ETA receptor antagonism by BQ-123 (10
76
M, a,b) or ETB receptor desensitization by exposure to SRTX
S6c (361078 M, c,d) on cumulative concentration-response curves to ET-1 in small mesenteric arteries from rats 5 weeks (a,c) or 12
weeks (b,d) after coronary artery ligation (post-MI) or sham-operation (sham-op). Agonist responses are expressed as a percentage
of the maximal contraction to KCl (60 mM) and are means+s.e.mean (n=6–8).
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on responses elicited by doses of ET-1 between 10713 and
3610710 M (Figure 4a). At 12 weeks post MI the rightward
shift was parallel but the magnitude of the shift was reduced
relative to that in the sham-operated control arteries (Figure
4b). The pD2 values could not be calculated for the studies
involving BQ-123 as maximum responses were not reached in
any group.
Desensitization of ETB receptors following exposure to a
supramaximal concentration of SRTX S6c (LaDouceur et al.,
1993; Mickley et al., 1997a) was confirmed by loss of response
to a second exposure to SRTX S6c (not shown). Desensitiza-
tion of the ETB receptor had no eect on responses to ET-1 in
arteries from sham-operated or 5-week post-MI rats (Figure
4c,d). In contrast, the ET-1 CRC in arteries from 12-week
post-MI rats was shifted to the left following ETB receptor
desensitisation so that it became superimposable on the ET-1
CRC obtained in arteries from sham-operated animals (Figure
4d, pD2 values of 9.4+0.2 and 9.4+0.3 respectively, n=6 per
group).
Combined removal of ETA and ETB receptor influence was
achieved by exposure to a supramaximal concentration of
SRTX S6c in the presence of BQ-123. In comparison to ETA
receptor blockade alone, addition of ETB receptor desensitiza-
tion resulted in an increased rightward shift of responses to low
concentrations of ET-1 at 5 weeks post sham-operation or MI
(Figure 5a). In vessels from 5-week post-MI rats the threshold
concentration for ET-1 increased from 3610713 M with BQ-
123 alone to 3610710 M with additional exposure to SRTX
S6c (Figure 5a). Responses to concentrations of ET-1 above
1078 M were similar whether BQ-123 was administered alone
or in combination with ETB receptor desensitization. This
dierential eect of BQ-123 or in combination with SRTX S6c
on the ET-1 CRC was not present in arteries from rats 12
weeks post-MI.
Discussion
Although it is known that plasma levels of ET-1 increase
during the progression of CHF following MI (Tomoda, 1993;
Omland et al., 1994), little is known of the receptors mediating
the vascular eects of ET-1 in these conditions. The present
study demonstrates that vascular responsiveness to ET-1
decreases progressively in the period following MI in the rat.
Loss of responsiveness is not associated with increased local or
systemic ET-1 synthesis but is temporally linked to upregula-
tion of ETB receptor expression in the smooth muscle medial
layer. Early after MI ETB receptors play a role in mediating
contraction in response to low concentrations of ET-1, but
with time post-MI the upregulated ETB receptor appears to
become linked to pathways that inhibit rather than potentiate
contraction.
In small mesenteric arteries from sham-operated animals
the dominance of ETA receptor mRNA in the smooth
muscle medial layer is reflected in the eectiveness of the
ETA receptor antagonist, BQ-123 as an inhibitor of ET-1
mediated contraction. Thus, the ETA receptor is the major
player in regulation of ET-1 induced contraction in these
arteries, as in most arteries studied (Davenport et al., 1995).
However, responses to very low concentrations of ET-1
persist in the presence of BQ-123 in these vessels consistent
with previous studies showing that, in addition to ETA
receptors, high anity ETB receptors can mediate arterial
smooth muscle contraction (Sumner et al., 1992; Teerlink et
al., 1994; Mickley et al., 1997a; McCulloch et al., 1998).
Binding studies have shown that ETB receptors are relatively
few in number in smooth muscle, even when ETB mediated
responses are much more significant than those found here
(Gray et al., 1994; Teerlink et al., 1994; Davenport et al.,
1995). The lack of detectable ETB receptor mRNA or
immunoreactivity in the medial layer of arterial sections
from sham-operated rats is consistent with the inability of
the selective ETB receptor agonist SRTX S6c to evoke
reproducible contraction in small mesenteric arteries. In
these arteries the ETB receptor is localized almost exclusively
to the endothelial layer consistent with the presence of ETB
receptors on these cells. However, these endothelial receptors
have no relevance to the functional studies presented here as
the endothelium was removed prior to commencement of the
studies.
Figure 5 The eect of combined ETA receptor antagonism, by BQ-123 (10
76
M), and ETB receptor desensitization, by exposure to
SRTX S6c (361078 M), on cumulative concentration-response curves to ET-1 in small mesenteric arteries from rats 5 weeks (a) or
12 weeks (b) after coronary artery ligation (post-MI) or sham-operation (sham-op). Agonist responses are expressed as a percentage
of the maximal contraction to KCl (60 mM) and are means+s.e.mean (n=6– 8).
Vascular ETB receptor upregulation post MI 1741G.A. Gray et al
British Journal of Pharmacology, vol 130 (8)
In vessels from rats at 5 weeks post MI, responses to ET-1
were similar to those seen in the age-matched arteries from
sham-operated animals. However the ETA antagonist resistant
portion of the response to low concentrations of ET-1 was
more marked in post-MI than in sham-op arteries. In these
vessels, the ET-1 CRC was shifted in parallel only when ETA
receptor blockade was combined with ETB receptor desensi-
tization, suggesting a role for contractile ETB receptors.
However, the SRTX S6c response was not increased in the 5
week post-MI vessels, nor was there any evidence for increased
immunoreactive ETB receptor or ETB receptor mRNA in the
smooth muscle media at this time point. This result and the
fact that ETB desensitization alone had no eect on responses
to ET-1 suggests that existing ETB receptors may regulate the
activation of the ETA receptor through intracellular crosstalk
(Fukuroda et al., 1994b; Clozel & Gray, 1995; Mickley et al.,
1997a; Ozaki et al., 1997), rather than by direct activation of
receptor signalling mechanisms that lead to contraction.
Investigation of ET-1 induced contraction in arteries from
12 week post-MI rats demonstrated progressive loss of
sensitivity, corresponding with previous studies in vitro and
in vivo that have demonstrated reduced constrictor and pressor
responses to ET-1 post-coronary artery ligation (Fu et al.,
1993). Loss of contractile responsiveness to ET-1 is unlikely to
be due to smooth muscle dysfunction as the maximum
responses to potassium and phenylephrine were conserved.
The ETA receptor antagonist, BQ-123, caused a parallel shift in
the ET-1 concentration-response curve demonstrating that
responses to ET-1 in these vessels were mediated predomi-
nantly by ETA receptors. Down-regulation of ET receptor
binding sites has been observed in cultured vascular smooth
muscle cells following incubation with high concentrations of
ET-1 (Hirata et al., 1988) and in conditions where local ET-1
concentration is increased in vivo (Schirin et al., 1997).
However, in the present study the circulating concentration of
ET-1 was not significantly increased and there was no evidence
for recruitment of vascular smooth muscle cells as a site for
ET-1 synthesis, as has been shown in other pathologies
(Schirin et al., 1996; 1997; Rossi et al., 1999). Quantification
of receptor expression was not possible in the small mesenteric
arteries, but no gross alteration in the amount of ETA receptor
mRNA present in the smooth muscle medial layer was evident.
However, in contrast to sham-operated controls there was a
marked increase in ETB receptor mRNA and protein
associated with the smooth muscle of these arteries. In
previous studies increased ETB receptor expression has been
associated with increased contractile responsiveness to ETB
selective agonists like SRTX S6c (Barber et al., 1996; Adner et
al., 1998). In the present study, SRTX S6c induced
contractions were not increased in arteries from 12-week
post-MI rats relative to sham-operated controls. In fact, fewer
arteries in this group responded to SRTX S6c than in controls.
The role of the up-regulated ETB receptor became clear after
desensitization of the ETB receptor, a procedure which we have
shown previously to induce similar eects to ETB receptor
blockade using a specific antagonist (Mickley et al., 1997a). In
arteries from 12-week post MI rats, ETB receptor desensitiza-
tion caused a leftward shift in the ET-1 concentration-response
curve, restoring responses to control levels. These results
suggest that the up-regulated ETB receptor is linked to
mechanisms that inhibit rather than potentiate contraction.
Involvement of the endothelial ETB receptor can be ruled out
as a mechanism as removal of the endothelium was confirmed
by complete loss of relaxation to ACh. Inhibitory ETB
receptors have been suggested previously based on the actions
of ETB receptor desensitization or antagonists in endothelium-
denuded human gastroepiploic (Seo, 1996) or rat mesenteric
arteries (Mickley et al., 1997a). In a recent study, Iwasaki et al.
(1999) demonstrated endothelium-independent ETB receptor
mediated dilatation in rabbit mesenteric arteries. Dilatation
was inhibited by indomethacin suggesting a role for
vasodilator prostaglandins. This mechanism is however
unlikely to be involved in the present study as indomethacin
was present throughout all experiments. Intracellular crosstalk
has emerged as a mechanism for modulation of ETA receptor
mediated actions by ETB receptors (Fukuroda et al., 1994b;
Clozel & Gray, 1995; Mickley et al., 1997a; Ozaki et al., 1997).
However, in the present study, intracellular modification of
ETA receptor-mediated mechanisms seems unlikely as BQ-123
had similar eects in the presence or absence of ETB receptor
desensitization. There is evidence for a role of ETB receptors in
the clearance of ET-1 (Fukuroda et al., 1994a). It is possible
that ETB receptors have this role in CHF, and it cannot be
ruled out in the present experiments that desensitization might
have increased the local ET-1 concentration resulting in
augmented responses. Clearly, further investigation of the
mechanisms that cause ETB receptor up-regulation and their
role in pathophysiology is required.
Our data show that vascular responsiveness to ET-1 in
small arterioles is progressively reduced after MI. Loss of
responsiveness is related to up-regulation of an ETB receptor in
the smooth muscle media that is linked to inhibition of
contraction stimulated via the ETA receptor. There is no
evidence for additional production of ET-1 by smooth muscle
cells in these arteries. Increased systemic vascular resistance is
believed to contribute to the development of CHF post MI by
increasing afterload (Love & McMurray, 1996). If the
mechanisms described in this study were to persist during
progression to CHF then one would predict that an ETA
receptor antagonist would be of more benefit than an ETA/B
antagonist in reducing constrictor responses to the increased
circulating concentrations of ET-1 that accompany CHF.
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